The short version of solid-phase synthesis fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-04-18. Anything still debated is marked as such rather than presented as settled.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | About 3.1 kDa | 28 residues, N-terminally acetylated |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Freely soluble in water | Also soluble in aqueous buffers |
| Storage temperature | 2 to 8 °C | Protect from light and moisture |
| Common synonyms | Thymalfasin; Tα1 | Same peptide sequence |
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
==== India ==== In India, it is a Narcotics prescription-only (NRx) medication used for anxiety disorders, sometimes in combination with other drugs, i.e. the beta blocker propranolol. United Kingdom In the UK, etizolam has been classified as a Class C drug by the May 2017 amendment to The Misuse of Drugs Act 1971 along with several other designer benzodiazepine drugs.
== Implications == Since their introduction, modern measures of protein quality have been used to justify nutritional advice on the selection of protein sources and related public policy. As typical values for plant sources of protein are often considerably lower than those of animal protein, the PDCAAS and DIAAS have been used in discussions of the merit of plant-based diets, and arguments around plant-based diets have been used to evaluate the merits of protein quality measurements. Advocates of the importance of animal proteins point to the health benefits of such a diet, as well as the potential for protein insufficiency in a plant-based diet. On the other hand, advocates of a more plant-based diet point to the environmental impacts of meat production, the health risks of a diet rich in red or processed meat, as well as other unrelated health benefits of plant sources of protein. The choice of protein quality measurement also has implications for debates around plant-based diets. Plant sources of protein are more likely than animal sources to have a lower DIAAS than PDCAAS, so the use of DIAAS rather than PDCAAS may increase nominal discrepancies in protein quality between plant and animal sources. On the regulatory scale, this may affect how plant sources of protein may be marketed. For example, the USDA allows foods with at least 10% of RDI of protein to be labeled as a "good source" of protein, and for a food to be labeled "high" in protein, it must contain at least 20% of RDI, accounting for quality.
On 12 August 1990, Saddam "propose[d] that all cases of occupation, and those cases that have been portrayed as occupation, in the region, be resolved simultaneously". He called for Israel to withdraw from occupied territories in Palestine, Syria, and Lebanon, Syria to withdraw from Lebanon, and "mutual withdrawals by Iraq and Iran and arrangement for the situation in Kuwait." He called for a replacement of US troops, that mobilized in Saudi Arabia, with "an Arab force", as long as that force did not involve Egypt. He requested an "immediate freeze of all boycott and siege decisions" and a normalization of relations with Iraq. Bush was strongly opposed to any "linkage" between Iraq's occupation of Kuwait and the Palestinian issue. On 23 August, Saddam appeared on state television with Western hostages to whom he had refused exit visas. In the video, he asks a British boy, Stuart Lockwood, whether he is getting his milk, and goes on to say, through his interpreter, "We hope your presence as guests here will not be for too long. Your presence here, and in other places, is meant to prevent the scourge of war." Another Iraqi proposal communicated was delivered to US national security advisor Brent Scowcroft by an unidentified Iraqi official. The official communicated that Iraq would "withdraw from Kuwait and allow foreigners to leave" provided the UN lifted sanctions, allowed "guaranteed access to the Persian Gulf through the Kuwaiti islands of Bubiyan and Warbah", and allowed Iraq to "gain full control of the Rumaila oil field that extends slightly into Kuwaiti territory".
==== Putative receptor targets ==== The table highlights several common cannabinoids along with putative receptor targets and therapeutic properties. Exogenous (plant-derived) phytocannabinoids are identified with an asterisk while remaining chemicals represent well-known endocannabinoids (i.e., endogenously produced cannabinoid receptor ligands).
Sources: en.wikipedia.org
== Adverse effects == The most significant adverse effects associated with topiramate treatment are predominantly central nervous system (CNS) related. A notable proportion of patients, ranging from 11% to 28%, discontinue topiramate therapy due to adverse effects. People taking topiramate should be aware of the following risks:
== See also == State Sponsors of Terrorism (U.S. list) Specially Designated Nationals and Blocked Persons List United States sanctions on Bangladesh Caesar Syria Civilian Protection Act Rogue state Economic sanctions against the United States Permanent normal trade relations Arms Export Control Act Criticism of United States foreign policy European Union sanctions United Kingdom sanctions United States foreign adversaries
Polyhexamethylene biguanide hydrochloride is a fast-acting, broad-spectrum synthetic compound that binds to the cell envelope of both Gram-positive and Gram-negative bacteria, disrupting the bacterial cell membrane and enabling seepage of ions. PHMB has a long history of use as a contact lens cleanser, mouthwash and more recently in wound care. It is regarded as being quite safe to use as it has been incorporated as a preservative in cosmetics. A retrospective analysis of wound cleanser clinical efficacy and cost-effectiveness focused on polyhexamethylene biguanide solution, Ringer's solution or saline in 112 venous leg ulcer patients. The study group received the polyhexamethylene biguanide solution (n=59) and the control group received either Ringer's solution or saline (n=53). In both arms, ulcer healing patterns were evaluated. Within the first 3 months of treatment, a shorter time to healing was recorded in the study group when compared with the control group - 60% v. 28% with corresponding mean time to healing being 3.31 months (study group) compared to 4.42 months (control group) p= <0.0001. More patients in the polyhexamethylene biguanide group healed in the 6-month period when compared with the controls - 97% v. 89%. The authors concluded that optimization of the local wound environment was significantly influenced through cleansing with polyhexanide solution. In an in vitro model developed to compare the efficiency of wound-rinsing solutions, Kaehn et al.
In December 2012, the U.S. state of Washington became the first state to officially legalize cannabis in a state law (Washington Initiative 502) (but still illegal by federal law), with the state of Colorado following close behind (Colorado Amendment 64). On 1 January 2013, the first cannabis "club" for private marijuana smoking (no buying or selling, however) was allowed for the first time in Colorado. The California Supreme Court decided in May 2013 that local governments can ban medical cannabis dispensaries despite a state law in California that permits the use of cannabis for medical purposes. At least 180 cities across California have enacted bans in recent years. On 30 April 2024, the United States Department of Justice announced it would move to reclassify cannabis from a Schedule I controlled substance to the somewhat less restricted Schedule III. On 18 December 2025, Donald Trump signed an executive order to reclassify cannabis as a Schedule III drug. In December 2013, Uruguay became the first country to legalize growing, sale and use of cannabis. After a long delay in implementing the retail component of the law, in 2017 sixteen pharmacies were authorized to sell cannabis commercially. On 19 June 2018, the Canadian Senate passed a bill and Prime Minister Justin Trudeau announced the effective legalization date as 17 October 2018. Canada is the second country to legalize the drug. In November 2015, Uttarakhand became the first state of India to legalize the cultivation of hemp for industrial purposes.
Normative ESC values have also been established for pediatric age groups, and it has been demonstrated that ESC values begin to decrease in the eighth decade of life. ESC has the potential to be a useful tool for detecting small fiber neuropathies. It is highly sensitive, rapid, more accessible and less technically complex than current gold standard sudomotor function tests, and causes minimal-to-no patient discomfort, so very suitable for routine use.
Sources: en.wikipedia.org
== Awards == Awards for his work include the Award of Society of Polymer Science, Japan (1982), The Chemical Society of Japan Award for 1999, Chirality Medal (2001), Medal with Purple Ribbon (Japanese Government) (2002), Fujiwara Prize (2005), and the Japan Prize (2019). In 2020, he became a laureate of the Asian Scientist 100 by the Asian Scientist.
Both malate and oxaloacetate can be converted into phosphoenolpyruvate, which is the product of phosphoenolpyruvate carboxykinase, the first enzyme in gluconeogenesis. The net result of the glyoxylate cycle is therefore the production of glucose from fatty acids. Succinate generated in the first step can enter into the citric acid cycle to eventually form oxaloacetate.
The idea of a guerrilla organization was conceived as early as October 1941, months before the Philippines' entry to World War II. As early as 1941, Juan Feleo, a well-known peasant leader and member of the Partido Komunista ng Pilipinas (PKP), had begun to mobilize peasants in his home province of Nueva Ecija for the conflict. Pedro Abad Santos, The founding member of the Socialist Party of the Philippines, had also ordered Luis Taruc to mobilize forces in Pampanga. At the outbreak of World War II in the Philippines and the capture of Manila, top-ranking leaders of the PKP were captured by the Japanese military. Crisanto Evangelista, its founder, was among those who were captured and executed in 1942. Abad Santos was similarly captured but was released in 1943. Dr. Vicente Lava took the reins of the PKP and tried to re-organize the party. In February 1942, a "struggle conference" was held in Cabiao, Nueva Ecija to discuss organization, strategy, and tactics. Members of the PKP, the Popular Front Party, the League for the Defense of Democracy, KPMP, AMT, and KAP convened to create a structure for unified resistance against the Japanese. A united front tactic was agreed upon as a means of attracting the broadest sections of population, not necessarily communists. A three-front resistance was agreed upon: military, political, and economic. The military aim was to harass the Japanese continuously and keep it off-balance so as to prevent it from focusing on activities aimed at winning the goodwill of the people.
== Development == In the embryo, the epididymis develops from tissue that once formed the mesonephros, a primitive kidney found in many aquatic vertebrates. Persistence of the cranial end of the mesonephric duct will leave behind a remnant called the appendix of the epididymis. In addition, some mesonephric tubules can persist as the paradidymis, a small body caudal to the efferent ductules. The epoophoron is a homologous remnant in the female.
===== Behavioral treatments ===== A 2018 systematic review and network meta-analysis of 50 trials involving 12 different psychosocial interventions for amphetamine, methamphetamine, or cocaine addiction found that combination therapy with both contingency management and community reinforcement approach had the highest efficacy (i.e., abstinence rate) and acceptability (i.e., lowest dropout rate). Other treatment modalities examined in the analysis included monotherapy with contingency management or community reinforcement approach, cognitive behavioral therapy, 12-step programs, non-contingent reward-based therapies, psychodynamic therapy, and other combination therapies involving these. Additionally, research on the neurobiological effects of physical exercise suggests that daily aerobic exercise, especially endurance exercise (e.g., marathon running), prevents the development of drug addiction and is an effective adjunct therapy (i.e., a supplemental treatment) for amphetamine addiction. Exercise leads to better treatment outcomes when used as an adjunct treatment, particularly for psychostimulant addictions. In particular, aerobic exercise decreases psychostimulant self-administration, reduces the reinstatement (i.e., relapse) of drug-seeking, and induces increased dopamine receptor D2 (DRD2) density in the striatum. This is the opposite of pathological stimulant use, which induces decreased striatal DRD2 density.
Sources: en.wikipedia.org
It is a 28-residue synthetic peptide studied as an immune-modulating agent and approved as a drug in some countries. The sequence matches a naturally occurring fragment isolated from thymus tissue. It is not a hormone in the endocrine sense.
The name traces back to thymosin fraction 5, a crude thymus extract examined in the 1970s. Individual peptides in that mixture were labeled with Greek letters, and alpha-1 was one of them. The international nonproprietary name thymalfasin was assigned later.
No. Thymosin beta-4 contains 43 residues and binds actin, while thymosin alpha-1 contains 28 residues and acts on immune cells. The two sit in a historical naming group but share no sequence similarity, and they are not substitutes for one another.
Its sequence corresponds to the amino-terminal portion of prothymosin alpha, a larger protein present in many cell types. The isolated 28-residue peptide is a fragment of that protein rather than a separately encoded molecule, and laboratory material is produced by synthesis.